Numinus Announces the Music as Medicine Event Series

Numinus Announces the Music as Medicine Event Series

Music As Medicine   by Numinus  is a series of Meditative Musical Experiences & Creative Content Featuring Jon Hopkins, East Forest And Superposition

Numinus Wellness ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF) a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies is pleased to announce that it is launching Music As Medicine by Numinus a series of ceremonial concerts exploring the role music plays in psychedelic-assisted therapy and mental health. Music As Medicine by Numinus will feature a rotating roster of meditative and ambient musicians, including Jon Hopkins East Forest and Superposition, multimedia art, and immersive guided meditations.

"Music, community and connection have always played an important role in sacred ceremonies and are an integral component of psychedelic-assisted therapy and integration," says Payton Nyquvest , Founder and CEO, Numinus. "Through the Music as Medicine   by Numinus series, we are celebrating an emerging genre of meditative music and exploring the role that music can play as part of the healing process, while building connection across a community."

"Psychedelic therapies are moving into legality across the world, and yet it feels like no one is talking about the music that accompanies them," says Jon Hopkins . "In Indigenous psychedelic ceremonies," he adds, "the music is as important as the medicine, and has been for thousands of years. Music is how you navigate the space."

Following the recent announcement of Numinus' proposed expansion into the U.S., Music As Medicine   by Numinus will be hosted in various cities across the U.S. and Canada , celebrating Numinus' move into the U.S. and reinforcing its community in its home country of Canada . The first event is in Los Angeles on May 21, 2022 at the renowned venue, Lighthouse Immersive, and will consist of five hours of continuous and entrancing live music and visuals by a line-up of the preeminent artists in this emerging genre: Superposition, Justin Boreta , Matthew Davis' ambient project and East Forest. L.A.-based multimedia art studio Strangeloop, known for their captivating visuals for artists such as Lil NasX, Flying Lotus, and The Weeknd, will be fully enveloping the space with live projection-mapping intended to submerge guests in an all-sensory experience. The event will end with a live, 3D spatial-audio playback of Jon Hopkins ' most recent, acclaimed album, Music For Psychedelic Therapy, experienced in total darkness, followed by an intimate, live piano performance of "Sit Around the Fire".

"We are thrilled to be a part of the Music as Medicine by Numinus event series. The intention is to create a safe container for deep listening," says Justin Boreta . "This is the way this type of music should be experienced."

"Music to modern humans is like asking a fish what water is. With music more present than ever, I am excited to be fostering spaces that can serve as a spear tip of exploration and experimentation around using music as a tool for inner insight and growth," says East Forest.

Numinus is also showcasing its Music As Medicine   by Numinus concept at DoubleBlind's Mycelia Festival in Ojai, California , as well as other cities, which will be announced soon.

Tickets for the L.A. event go on sale Friday, April 29 at www.numinus.com/music-as-medicine-event . More information on the other dates will be released in the coming weeks.

About Numinus

Numinus Wellness (TSX: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model - including psychedelic production, research and clinic care - is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Learn more at www.numinus.com and follow us on LinkedIn , Facebook , Twitter , and Instagram .

Forward-looking statements

This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are "forward-looking statements". Forward-looking statements can be identified by the use of words such as "expects", "does not expect", "is expected", "believes", "intends", "anticipates", "does not anticipate", "believes" or variations of these words, expressions or statements, that certain actions, events or results "may", "could", "would", "might" or "will be" taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, dependence on obtaining and maintaining regulatory approvals, including the acquisition and renewal of federal, provincial, municipal, local or other licenses, and any inability to obtain all necessary government authorizations, licenses and permits to operate and expand the Company's facilities; regulatory or policy changes such as changes in applicable laws and regulations, including federal and provincial legalization, due to fluctuations in public opinion, industry perception of integrative mental health, including the use of psychedelic-assisted therapy, delays or inefficiencies or any other reason; any other factor or development likely to hamper the growth of the market; the Company's limited operating and profitability track record; dependence on management; the Company's need for additional financing and the effects of financial market conditions and other factors on the availability of capital; competition, including that of more established and better funded competitors; the impact of the Russia - Ukraine conflict on the global economy; the continued impact of the COVID-19 pandemic; and the need to build and maintain alliances and partnerships, including with research and development companies, customers and suppliers. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company's efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws.

Numinus Announces the Music as Medicine Event Series (CNW Group/Numinus Wellness Inc.)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/numinus-announces-the-music-as-medicine-event-series-301536055.html

SOURCE Numinus Wellness Inc.

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/April2022/29/c3807.html

News Provided by Canada Newswire via QuoteMedia

NUMI:CA
The Conversation (0)
Numinus to expand state-of-the-art psychedelics research laboratory

Numinus to expand state-of-the-art psychedelics research laboratory

Numinus Bioscience adds research space, enhances contract services,
accelerates IP development and increases psychedelic supply capacity

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI ), a global leader in supporting and expanding the safe, accessible and evidence-based use of psychedelic-assisted psychotherapies (PAP), is pleased to announce plans to significantly expand its psychedelics research laboratory by late 2021.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Regulatory approvals place Numinus lab at the forefront of global psychedelics research

Regulatory approvals place Numinus lab at the forefront of global psychedelics research

Numinus Bioscience adds Ketamine and LSD to licence to produce, assemble and sell a wide variety of psychedelic compounds

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI ), a global leader in supporting and expanding the safe, accessible and evidence-based use of psychedelic-assisted psychotherapies (PAP), has received new amendments under Canada's Controlled Drugs and Substances Act that enhance the Company's ability to lead psychedelics research and support the global psychedelics sector.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Numinus and Syreon Provide Psilocybin Compassionate Access Trial Update

Numinus and Syreon Provide Psilocybin Compassionate Access Trial Update

Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in collaboration with MAPS Public Benefit Corporation

Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in collaboration with MAPS Public Benefit Corporation

Trial enters pre-implementation stage having met several key milestones towards expanding access to patients with PTSD

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to share that the single-arm, open-label, compassionate access 1 trial for MDMA-assisted therapy has made significant progress towards treating patients with posttraumatic stress disorder (PTSD). This trial is being pursued in collaboration with MAPS Public Benefit Corporation (MAPS PBC) a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS) the leading developer of the treatment protocols, research, and MDMA-assisted therapy training programs.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Numinus Wellness Closes Q1 2021 with Strong Cash Position and Industry Firsts

Numinus Wellness Closes Q1 2021 with Strong Cash Position and Industry Firsts

Key milestones met in ongoing trials, expanding national footprint, and enhanced research
capabilities ensure Numinus' continued growth

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a health care and research company developing and delivering psychedelic-centred solutions to treat mental illness, substance abuse and trauma, today announced its financial results for the first quarter for the three months ended November 20, 2020 ("Q1 2021"). After achieving two industry firsts, launching new compassionate access trials, and augmenting its clinical and research activity, Numinus meaningfully expanded its industry presence in Q1 2021. All financial results are reported in Canadian dollars unless otherwise stated.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Person touching a cannabis plant; Australia map in flag colours.

ASX Cannabis Stocks: 10 Biggest Companies

While Australia has yet to legalise all forms of cannabis, the country is a growing medical cannabis and hemp market, with many companies manufacturing, researching and exporting the plant-based product.

Medical cannabis was federally legalised in 2016, and the export of cannabis from Australia was legalised in 2018. As for recreational use, the only state to legalise recreational use and possession so far is the Australian Capital Territory, which did so in 2020, but it did not establish a regulated recreational cannabis market.

The country's medical cannabis market has been steadily expanding in size and scope. A Penington Institute report shows that Australians spent approximately AU$400 million on medicinal cannabis in the first half of 2024, 72 percent higher than the AU$234 million they spent over the entirety of 2022.

Keep reading...Show less
Cannabis leaves, gavel.

Cannabis Round-Up: Rescheduling Faces New Roadblocks, SAFER Banking Act Gets Another Look

February 2025 was characterized by an evolving legislative landscape and important financial updates from major players.

These developments underscore the complex and dynamic nature of the sector as it continues to navigate legal, financial, and regulatory challenges while experiencing ongoing growth and evolution.

Discussions around cannabis rescheduling, changes in federal agency leadership, state-level legalization efforts, and financial reports from key companies all contributed to a month of notable activity in the cannabis space.

Keep reading...Show less

Trulieve Announces Launch of Onward: A Premium THC Beverage

Available now online and coming soon to select Total Wine locations in Florida

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced the launch of Onward, a premium, non-alcoholic THC beverage offering a modern alternative for social occasions. These Farm Bill compliant beverages are available now online and coming soon to select Total Wine locations in Florida .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Cronos Group Inc. to Hold 2024 Fourth Quarter and Full-Year Earnings Conference Call on February 27, 2025

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") will hold its 2024 fourth-quarter and full-year earnings conference call on Thursday, February 27, 2025 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks.

To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations . To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on the Company's website.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Trulieve to Open Dispensary in Columbus, Ohio

New Franklin County location will host grand opening celebration Friday, February 21 st

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced the opening of a new dispensary in Columbus, Ohio .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve to Open Medical Cannabis Dispensary in Middleburg, Florida

New Clay County location will host grand opening celebration Friday, February 14 th

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced the opening of a new medical cannabis dispensary in Middleburg, Florida .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×